Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.17 USD
+0.04 (3.54%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.15 -0.02 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 61 - 80 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Pioneering Suprachoroidal Delivery; Assume Coverage at OP; Adding to BIL
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Eyes Wide Open: Setting Our Sights on a New Frontier in Ocular Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Patient Dosing Starts in the China Registration Study of XIPERE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Catching The Next Wave of Innovation: Highlights from Vitreoretinal KOL Call
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Still About Safety for CLS-AX Cohort 2 Results by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Dose-Escalation Data for CLS-AX in wAMD on Track For YE2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE Approved for Macular Edema Associated With Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE''s Approval Takes Some Platform Risk off the Table-PT Raised to $17
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE Approval Validates Clearside''s SCS Microinjector
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Partner Reports Positive Preliminary Data in Diabetic Retinopathy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
RGNX''s Suprachoroidal Gene Therapy Data Derisk Clearside''s SCS Injector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
RGX-314/wAMD Safety Requires Monitoring at Higher Doses; No Read Thru to CLS-AX
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L